Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 Infection

14 november 2026 bijgewerkt door: Beijing Xunsheng Biomedical Research Co., Ltd.

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV Infection in Subjects Who Are Positive for HPV16/18

This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All participants must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. Subjects who meet all inclusion criteria will report to the study site on Day 0 and be assigned to a specific dosage group. Following the completion of eligibility assessments and baseline safety evaluations, subjects will receive an injection of the HPV-targeting nucleic acid therapeutic on Day 0, Day 21 (±3 days), and Day 42 (±3 days).

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Gedetailleerde beschrijving

This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All subjects must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. The study is divided into two phases:

Phase 1: This phase includes two dosage groups-0.05 mg and 0.5 mg. Subjects will be assigned to one of these dosage groups according to pre-established allocation rules and will receive a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.

Phase 2: This phase consists of a 0.5 mg dosage group, with subjects receiving a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.

Studietype

Ingrijpend

Inschrijving (Geschat)

300

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Hebei
      • Qinhuangdao, Hebei, China
        • Werving
        • Beidaihe Hospital of Qinhuangdao City
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 64 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  1. Participants must be aged 18-64 years (inclusive); only female participants will be enrolled.
  2. Subjects will voluntarily join the study and sign an informed consent form.
  3. During the screening period, there shall be no clinically significant abnormalities in medical history, physical examination, vital signs, 12-lead electrocardiogram, or clinical laboratory test results; the investigator will determine that the subject is suitable for enrollment.
  4. During the screening period, the HPV16/18 genotyping nucleic acid test result must be positive, and the subject must meet one of the following criteria: (1) a positive HPV16/18 test record during the screening period, with no current evidence of intraepithelial lesions; (2) a diagnosis of high-grade intraepithelial lesions of the cervix, vagina, or vulva confirmed by histopathological examination, with the subject meeting the enrollment criteria and treatment plan after specialist assessment; (3) the subject has previously undergone surgery or other local treatment for a related intraepithelial lesion, and the HPV16/18 test remains positive during the screening period, with no residual lesions currently present, or histopathological examination confirms the presence of residual or recurrent low-grade or high-grade intraepithelial lesions. (HPV subtype test results obtained within 30 days prior to administration, as well as TCT results and pathological biopsy results obtained within 90 days prior to administration, are acceptable).
  5. Fertile subjects (defined as females who have not undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, and whose menopause has occurred for ≥12 months) must agree to use highly effective contraceptive measures with their partner during the study treatment period and for at least 12 months after the final dose, including oral contraceptives, intrauterine devices, barrier contraception combined with spermicidal agents, or partner sterilization.
  6. Female subjects during the screening period must have negative serum or urine pregnancy tests and must not be in the lactation period. Be willing to undergo pregnancy testing during the screening period, before each dose administration, and at the end of the study.
  7. Be willing and able to comply with and complete all study procedures.

Exclusion Criteria:

  1. Presence of any skin condition on the upper arm that may interfere with the assessment of the injection-site reaction (ISR), including but not limited to extensive tattoos, scars, rashes, infections, or wounds.
  2. Presence of severe poor venous condition that precludes blood sample collection as required by the protocol.
  3. Presence, during screening, of an acute infection of the genital or anal region requiring systemic anti-infective therapy (excluding HPV infection).
  4. Pregnancy or lactation; or a history of miscarriage within the 3 months preceding screening.
  5. Any medical condition judged by the investigator to increase the risk of biopsy-related bleeding.
  6. In addition to the study indication, any clinically significant acute or chronic disease that, as judged by the investigator, may increase the risk of trial drug exposure or interfere with study evaluation.
  7. Inadequacy for adequate colposcopic evaluation.
  8. Presence of any of the following conditions: 1) Pathological confirmation of adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma in the target lesion during the screening period; 2) A history of malignant tumors of the cervix, vagina, vulva, or anal region; 3) Colposcopic findings during the screening period suggesting a suspicious malignant tumor; 4) Having undergone total hysterectomy, thereby precluding assessment of cervical lesions (however, if the uterus was resected solely for benign lesions while the patient still has vulvar/vaginal/anal lesions, this does not automatically disqualify the subject); 5) Presence of any other uncurated malignant tumor in a site other than those described above within 5 years prior to enrollment (excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc.).
  9. Screening: Use of immunosuppressants continuously (for more than 7 days) within the 30 days prior to screening, including but not limited to: glucocorticoids (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.
  10. Screening: Receipt of any medication known to have anti-HPV activity (including injectable HPV prophylactic vaccines) within the 30 days prior to screening.
  11. History of severe allergic reactions (requiring hospitalization), severe reactions to any medication or vaccine injection, or any known or suspected allergy to any component of the study drug or formulation.
  12. Presence of uncontrolled systemic chronic diseases.
  13. Laboratory tests during the screening period meeting any of the following criteria: 1) Hemoglobin <90 g/L; 2) Neutrophil count <1.0 × 10⁹/L; 3) Platelet count <80 × 10⁹/L; 4) AST or ALT> 1.5 × ULN; 5) Creatinine clearance <60 mL/min (using the Cockcroft-Gault formula); 6) International Normalized Ratio (INR)> 1.5 × ULN; 7) HIV antibody positive; 8) HCV antibody positive (and HCV RNA positive); 9) HBsAg positive (and HBV DNA positive); 10) Active syphilis (RPR/TPPA positive and requiring treatment).
  14. Any history of alcohol or drug abuse that the Investigator deems likely to affect subject safety or study adherence.
  15. Subjects that the Investigator deems unwilling or unable to adhere to the requirements of the study protocol.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: AVL-1100

Dosage and administration for the nucleic acid-based therapeutic injection for HPV infection: A total of 3 injections are to be administered, with an interval of three weeks between each dose. The product is to be administered via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the subject must remain under observation for 60 minutes, during which time a safety assessment will be conducted. Provided no serious adverse events occur, the subject may proceed with the scheduled follow-up visits.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Safety and tolerability
Tijdsspanne: Up to Day 300

Dose-limiting toxicities (DLTs), as well as the incidence and severity of adverse events, etc.

Up to Day 300

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Effectiveness
Tijdsspanne: Up to Day 300

The rate of HPV16/18 viral reversion to negativity at the final visit.

Up to Day 300
Effectiveness
Tijdsspanne: Up to Day 300

The degree of lesion regression assessed by histopathological evaluation at the final visit.

Up to Day 300
Immunogenic
Tijdsspanne: Up to Day 300

Cell-mediated antigen-specific immune response against HPV16/18.

Up to Day 300

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 oktober 2025

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

28 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • AVL-1100-01

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren